Frontotemporal Degeneration News and Research

RSS

New protein atlas identifies distinct subtypes of neurodegenerative diseases

Neurodegenerative diseases form a tangled biological web with overlapping molecular signatures and symptoms. To decode this complexity, a multi-institute collaboration led by St. Jude Children's Research Hospital scientists developed the pan-neurodegeneration atlas (PanNDA).

23 Mar 2026

Blood and brain biomarkers transform how doctors confirm Alzheimer’s disease

A new Lancet review proposes a three-wave diagnostic pathway that combines clinical expertise with blood, CSF, and PET biomarkers. This approach aims to deliver earlier, more accurate, and more equitable Alzheimer’s disease diagnosis worldwide.

24 Sep 2025

Uncovering the secrets of ‘SuperAgers’ and cognitive longevity

For 25 years, scientists at Northwestern Medicine have been studying individuals aged 80 and older - dubbed "SuperAgers" - to better understand what makes them tick.

8 Aug 2025

Study offers new clues to early detection of frontotemporal dementia in middle age

Dementia usually affects older people, so when it occurs in middle age, it can be hard to recognize. The most common form is frontotemporal dementia (FTD), which is often mistaken for depression, schizophrenia, or Parkinson's disease before the correct diagnosis is reached.

16 May 2025

New scientific clue could unlock key cellular pathway leading to neurodegenerative diseases

In Nature Neuroscience, UConn School of Medicine researchers have revealed a new scientific clue that could unlock the key cellular pathway leading to devastating neurodegenerative diseases like Alzheimer's disease, and the progressive damage to the brain's frontal and temporal lobes in frontotemporal degeneration (FTD) and the associated disease amyotrophic lateral sclerosis (ALS).

14 Mar 2025

Penn-led consortium to advance imaging of brain diseases

A Penn Medicine-led consortium of radiology and chemistry researchers across the United States will advance imaging of diseases like Parkinson's by testing radiotracers they identified that illuminate α-synuclein (αSyn) or 4R tau proteins on positron emission tomography (PET) scans.

11 Dec 2024

C-Path announces important leadership appointments in neurology and Alzheimer's research

Critical Path Institute (C-Path) today announced key leadership appointments: Diane Stephenson, Ph.D., has been promoted to Vice President of Neurology, and Nadine Tatton, Ph.D., has been welcomed as the new Executive Director of C-Path's Critical Path for Alzheimer's Disease (CPAD) Consortium.

7 Nov 2024

Protein biomarkers in spinal fluid offer promise for early progressive supranuclear palsy diagnosis

Progressive supranuclear palsy (PSP), a mysterious and deadly neurological disorder, usually goes undiagnosed until after a patient dies and an autopsy is performed.

3 Jul 2024

Smartphone app shows promise in detecting early signs of frontotemporal dementia

UCSF-led research shows smartphone cognitive testing is comparable to gold-standard methods; may detect FTD in gene carriers before symptoms start.

1 Apr 2024

C-Path announces formation of new task force to foster drug development for Progressive Supranuclear Palsy

Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform, dedicated to advancing therapeutic development for Progressive Supranuclear Palsy.

26 Mar 2024

Scientists uncover key protein aggregation in frontotemporal dementia

Most neurodegenerative diseases, including dementias, involve proteins aggregating into filaments called amyloids.

6 Dec 2023

UTHSC researchers secure $308,000 grant from Department of Defense for dementia study

Repeated traumatic brain injuries (TBI) in soldiers and military personnel can cause behavioral, neurological, and cognitive effects and lead to dementia.

19 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

17 recommendations for better communication with study participants affected by early stopping of clinical trials

Participants in clinical trials can feel abandoned and adrift when their studies end early and they are the last to be informed, or they hear about it first from news or social media.

2 Aug 2022

Cell-hobbling fibrils found across diverse neurodegenerative diseases

Take a cell-deep tour of a brain afflicted with Alzheimer's disease, and you will find minuscule clumps of protein that seem suspicious. Ever since the 1980s, when neuroscientists began identifying these protein tangles, researchers have discovered that other brain diseases have their own tangled-protein signatures.

4 Mar 2022

Mount Sinai researchers use cerebral organoids to study frontotemporal dementia

Frontotemporal dementias are a group of fatal and debilitating brain disorders for which there are no cures.

26 Jul 2021

ATN framework can be extended to detect frontotemporal degeneration

Alzheimer's disease and related diseases can still only be confirmed in deceased patients' brains via autopsy.

20 Jul 2021

Research identifies distinctive inflammatory signature in a genetic form of ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that strikes nearly 5,000 people in the U.S. every year. About 10% of ALS cases are inherited or familial, often caused by an error in the C9orf72 gene.

16 Jun 2021

Expert panel provides guidance for optimized design of early drug trials for Alzheimer's, related dementias

An expert panel convened by the Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer's disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias.

19 May 2021

NeuroVision Imaging receives ADDF funding to develop biomarker tests for Alzheimer's disease

NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer's Drug Discovery Foundation to support developing reliable, affordable biomarker tests for Alzheimer's disease and other forms of dementia and neurodegenerative disorders.

3 Feb 2021